NICE rejects Gilead CAR-T cancer cell therapy

Aug 28, 2018

The National Institute for Health and Care Excellence, Britain's state-funded health service, has deemed Gilead's Yescarta, a CAR-T cell therapy for certain forms of blood cancer, too expensive. The drug is the first CAR-T therapy assessed by NICE.

Gilead was aiming to get the drug approved for use on the National Health Service. This rejection comes after just being approved by the the European Commission for two aggressive forms of non-Hodgkin lymphoma. Yescarta has also been approved by the U.S. Food and Drug Administration since late last year.

The Yescarta treatment is a new approach to fighting cancer and involves extracting infection-fighting cells from a patient. These cells are then genetically engineered to recognize cancer cells and infused back.

The U.S. list price for Yescarta is $373,000 while the UK price remains confidential.

Read the Reuters report

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments